Valacyclovir Shows Promise in Treating Herpes Zoster Ophthalmicus, Study Finds
Recent research presented at the American Academy of Ophthalmology highlights the benefits of valacyclovir in treating herpes zoster ophthalmicus (HZO). Led by Dr. Elisabeth Cohen, the study found that valacyclovir significantly reduces the risk of new or worsening eye disease and decreases the need for neuropathic pain medications. These findings support the use of valacyclovir as a key treatment option for improving the quality of life in HZO patients.
New ‘Dual Mutant’ Strains of H1N1 Influenza Detected in the U.S.
Recent reports from the CDC highlight the emergence of new ‘dual mutant’ strains of H1N1 influenza in the U.S., raising concerns about their impact on flu antiviral medication. These mutations may reduce the effectiveness of oseltamivir (Tamiflu) but not other medications. While still relatively rare, flu vaccination is recommended as a preventive measure.
Hyundai Bioscience to Conduct Global Clinical Trials for Dengue Antiviral Candidate
Hyundai Bioscience, a biotechnology company from South Korea, is focusing on global clinical development for a Dengue antiviral candidate to secure emergency use authorization. The CEO plans to conduct clinical tests targeting all Dengue virus serotypes, aiming for early administration of an effective antiviral drug. With a rise in Dengue cases globally, especially in the Americas, the need for a specific treatment is crucial. Hyundai Bioscience’s initiative in conducting extensive clinical trials signifies a significant step towards addressing the urgent need for a Dengue antiviral solution.
NIH Discontinues COVID-19 Treatment Guidelines
The National Institutes of Health (NIH) has discontinued its guidance on COVID-19 treatment as the availability of treatments like Pfizer’s Paxlovid has evolved. The decision reflects the evolving landscape of COVID-19 treatment and the decreasing frequency of meetings and discussions by the guideline group.
Kimer Med Secures $1.3 Million Contract for Antiviral Drug Development
Kimer Med, a biotech startup in New Zealand, has secured a $1.3 million contract to advance antiviral drug development. The focus is on developing new antiviral drug candidates for the treatment of alphaviruses, which can cause significant human and animal disease. Kimer Med has shown progress in developing antivirals with efficacy against various viruses, including Dengue and Zika.